Rising prevalence of cardiovascular diseases and rapid advancements in minimally invasive procedures are fueling the growth ...

Based on the finalized national coverage determination (NCD) for transcatheter tricuspid valve replacement, Medicare will ...

Samman, A. and Babi, A. (2025) Pulmonary Septic Emboli Following Endocarditis: A Case Report. Open Journal of Clinical ...

Payment will be provided when TTVR is delivered for an FDA-approved indication in the context of a CMS-approved study.

Cardiogenic shock remains a challenging clinical syndrome characterized by critically impaired cardiac output, systemic hypoperfusion, and high mortality ...

The final U.S. Medicare national coverage determination for transcatheter tricuspid valve replacement (TTVR) devices comes ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of ...

Laplace Interventional, a US-based medical device company focusing on transcatheter valve technology, recently announced the ...

Laplace Interventional announced today that it completed a Series C financing round to support its prosthetic heart valve technology.

US medical device company Laplace Interventional has completed a Series C financing round to support the completion of an early feasibility study (EFS) of its transcatheter tricuspid valve (TTV) ...

A first of its kind surgery to help people with a specific type of heart failure is going through clinical trials at Providence St. Vincent’s.

Atrial functional mitral regurgitation (AFMR) is a common type of MR linked to high rates of heart failure, highlighting the need to understand its prognostic factors. Tricuspid regurgitation (TR) is ...